405 related articles for article (PubMed ID: 35848574)
1. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19.
Kapur R; Okumura K; Feola N; Keller M; Dhand A
Cureus; 2023 May; 15(5):e38867. PubMed ID: 37313067
[TBL] [Abstract][Full Text] [Related]
3. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.
Yetmar ZA; Bhaimia E; Razonable RR
Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253
[TBL] [Abstract][Full Text] [Related]
4. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Razonable RR; Tulledge-Scheitel SM; Hanson SN; Arndt RF; Speicher LL; Seville TA; Larsen JJ; Ganesh R; O'Horo JC
Open Forum Infect Dis; 2022 Oct; 9(10):ofac411. PubMed ID: 36213724
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
[TBL] [Abstract][Full Text] [Related]
6. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.
Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
[TBL] [Abstract][Full Text] [Related]
8. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges.
Kapur R; Okumura K; Ohira S; Isath A; Gandhi A; Keller M; Nog R; Gass A; Spielvogel D; Lansman S; Dhand A
Cardiol Rev; 2024 Feb; ():. PubMed ID: 38334977
[TBL] [Abstract][Full Text] [Related]
11. Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis.
Tucker M; Azar MM; Cohen E; Gan G; Deng Y; Foppiano Palacios C; Malinis M
Transpl Infect Dis; 2022 Aug; 24(4):e13876. PubMed ID: 35684932
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
[TBL] [Abstract][Full Text] [Related]
13. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
14. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Razonable RR; O'Horo JC; Hanson SN; Arndt RF; Speicher LL; Seville TA; Hall ST; Pike ML; Heyliger A; Larsen JJ; Ganesh R; Tulledge-Scheitel SM
J Infect Dis; 2022 Nov; 226(10):1683-1687. PubMed ID: 36124696
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
Yetmar ZA; Yao JD; Razonable RR
J Med Virol; 2023 Jun; 95(6):e28885. PubMed ID: 37334976
[TBL] [Abstract][Full Text] [Related]
16. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
[TBL] [Abstract][Full Text] [Related]
19. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
20. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
